Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Updates from ASH 2024: Patient Preferences and Shared Decision Making in Hematologic Cancers : Episode 5
Advancing Hematologic Care and the Future of Shared Decision-Making
Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
Now Viewing
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- In what ways do these studies’ data collectively advance our understanding of unmet needs in hematologic cancer management, and how can their findings shape future clinical practices?
- How can the findings presented at ASH 2024 shape the next generation of shared decision-making models for patients with hematologic cancers?
- What are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?
Related Videos
Related Content
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
November 26th 2025Article
The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.
Read More
